The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
about
Predicting Clinical Outcomes Using Molecular BiomarkersSame Data; Different InterpretationsPostapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence.Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysOutcome measures in trials: the systematic reviewer's point of view.Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.2015 and human cancer: back to overall survival.Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY.Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.The OlympiAD trial: who won the gold?Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.The U.S. Health Care Crisis Continues: A Data Snapshot.Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?Industry Perspective on Biomarker Development and Qualification.Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.Budget impact and cost-effectiveness: can we afford precision medicine in oncology?Combining drugs and extending treatment - a PFS end point is not sufficient.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer.Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
P2860
Q26747424-B4D26574-EECA-431E-890C-F7C2831D2663Q31125419-54D561F8-3628-48A9-B126-775AF6083209Q33647393-29E8F72B-1E2D-4842-904D-93FC4968BD5CQ33921813-7F14991D-A58F-4275-A7B9-ECCB46E1F3A7Q36094655-859B53D7-3C0B-44D6-AA7E-7EF42E70DDA2Q37290101-DF281073-186B-4722-A595-B933F58C935FQ38646348-E4316235-8853-478D-98D1-96D416C68747Q38822094-9A7E40CC-65FF-4459-AD74-0C206AF3A8FCQ38880510-7B8CC603-AF45-4F2D-B2E1-76943F101285Q38891200-F7D5DEF6-4C67-4ED0-8502-8CE7802C2206Q39002683-029D19EF-7A5F-4C9E-A51A-1F5EA4E73DA4Q39391967-9020304F-8D8F-4A7A-A44A-3968F41AE024Q39582320-51B39BC6-F5DB-4D16-892C-42377E2880DEQ39666107-DD2544A5-1D42-45FC-A539-55D9A21D5B09Q41503758-6F97ECC3-52C5-4C6B-A86A-138C27C12693Q42281334-B5FCC1E9-D5D4-4442-B724-5DD98EF6B2FBQ47132052-F0E9842D-D5E5-4AD6-A726-3997F947335AQ47207279-18983E02-8185-418A-BABC-B5FE5E68809EQ47269814-85797D37-60BD-456C-8F2C-14FC787AFC30Q47403883-64081F72-E59D-46FE-B99E-FF1F82A5E80DQ47430316-DB63D81C-0ECC-40C6-B93E-F62BCF830193Q48142490-30EBE538-43A7-47BB-AA7C-EF9C5CD4226FQ48196689-6EC52EAB-6AD9-4201-A881-5708629BB70FQ49969133-12C31923-8125-40A6-BD80-B6F7275DB4B9Q50529551-4AC6719D-D9DB-4DB6-BE6A-99CA7BF5945DQ50597191-2E0FE52C-CB8C-44B2-98AC-B46C42131278Q52598812-6E1F9B99-6362-4F00-8D21-36E0F6756D8AQ52644314-02B8949B-75DA-4B2D-AA31-E554C25509FBQ52990848-952A9E7F-9FB6-480A-8244-ED81C6DF6E0FQ53110057-250E0E16-1967-4426-A8E6-4F23FAD7B9D2Q53717818-704FE131-D61C-4CEB-BB95-A969240DC06FQ55119011-D86936FC-EBF0-41D0-9CEC-38D8DD77211FQ55210410-F03E9427-EA34-4A36-9D07-AD9977166583
P2860
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Strength of Association Be ...... of Trial-Level Meta-analyses.
@en
type
label
The Strength of Association Be ...... of Trial-Level Meta-analyses.
@en
prefLabel
The Strength of Association Be ...... of Trial-Level Meta-analyses.
@en
P2093
P1476
The Strength of Association Be ...... of Trial-Level Meta-analyses.
@en
P2093
Andrae Vandross
Mauricio Burotto
P304
P356
10.1001/JAMAINTERNMED.2015.2829
P50
P577
2015-08-01T00:00:00Z